Zydus Cadila has announced to boost its production of hydroxychloroquine (HCQ) to 30 metric tonnes (15 crore tablets of 200mg) per month to cater to the increase in demand expected due to rising cases of COVID-19.
The company will be supplying the drug to the Indian Council of Medical Research (ICMR) at a reduced price of a little over Rs 3 per tablet, Zydus group chairman Pankaj Patel said in a statement.
There is enough stock in the country and, if needed it can be scaled up to 50 mt (25 crore tablets), he added.
The company decided to ramp up the drug production to facilitate the government’s decision to build up a stock of 10 crore dosages of the HCQ for the country.
ICMR recently advised the use of HCQ for prevention of COVID-19 infection among high-risk categories of population involving healthcare workers and relatives of confirmed patients. On April 7, the government had partially eased the export ban on HCQ, reportedly after a demand from the US.